15-LOX-1 Modulation of Colon Cancer Promotion by Linoleic Acid
亚油酸对 15-LOX-1 促进结肠癌的调节
基本信息
- 批准号:9886073
- 负责人:
- 金额:$ 35.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-01 至 2020-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcidsAdvocateAffectAlkaline PhosphataseAmerican dietAnimalsArachidonate 15-LipoxygenaseAttentionAutomobile DrivingAzoxymethaneBiological MarkersCDX2 geneCancerousCell Differentiation processCell ProliferationCell RespirationChemopreventive AgentColon CarcinomaColorectal CancerColorectal PolypConsumptionCoronary ArteriosclerosisCyclin D1DataDevelopmentDietDietary intakeDiseaseDown-RegulationEnzymesEpithelial CellsEventExposure toGene ExpressionGenerationsGenesHomologous GeneHumanIncidenceIntakeIntegration Host FactorsInterventionIntestinesKnock-outKnockout MiceKnowledgeLOX geneLeadLengthLentivirus VectorLigandsLinoleic AcidsLipoxygenase 1Messenger RNAMetabolismMolecularMusMutationNuclearOmega-6 Fatty AcidsOrganoidsOutcome MeasurePPAR gammaPatientsPhasePolyunsaturated Fatty AcidsProteinsRegulationRiskRodentRoleSignal TransductionSubfamily lentivirinaeSystemTamoxifenTestingTissuesTransgenic MiceTransgenic Organismsbeta cateninc-myc Genescolon cancer riskcolon tumorigenesiscolonic cryptcolorectal cancer preventioncolorectal cancer progressioncolorectal cancer riskdietary excessfunctional lossgain of functioninsightintestinal epitheliumliquid chromatography mass spectrometrymouse modelnovelpreclinical studypromoterpublic health relevancesmall hairpin RNAtumortumorigenesisvillin
项目摘要
DESCRIPTION (provided by applicant): Linoleic acid (LA) consumption is high in humans. LA increases azoxymethane (AOM)-induced colorectal tumorigenesis in rodents, but the impact of LA on colorectal cancer (CRC) in humans is unknown. 15- Lipoxygenase-1 (15-LOX-1) is the rate-limiting enzyme for the oxidative metabolism of LA to generate 13-S- HODE, a natural activating ligand of PPAR-gamma. PPAR-gamma suppresses aberrant Wnt/B-catenin signaling, a critical event initiating and driving CRC tumorigenesis. 15-LOX-1 is downregulated in human colorectal polyps and CRCs, but the influence of 15-LOX-1 on dietary LA modulation of CRC risk is unknown. In mice with intestinally targeted human 15-LOX-1 (15-LOX-1-Gut), we found that transgenic 15-LOX-1 expression suppressed CRC tumorigenesis, and 15-LOX-1 expression was downregulated in all experimentally-induced tumors. Furthermore, the increase in AOM-induced CRC with high LA dietary concentrations was repressed in 15-LOX-1-Gut mice; and 15-LOX-1 inhibited B-catenin activation. We therefore hypothesize that 15-LOX-1 loss in colonic epithelial cells is critical for excess LA to promote CRC tumorigenesis via augmenting Wnt/B-catenin signaling. We will test this hypothesis via 3 specific aims: Aims 1 and 2: Determine the effects of 15-LOX-1 expression (aim 1) and loss of expression (aim 2) in colonic epithelial cells on dietary LA promotion of CRC tumorigenesis and aberrant Wnt/B-catenin signaling. For aim 1, we will breed 15-LOX-1-Gut and Apc580mu mice to generate Apc580mu-15-LOX-1-Gut mice and examine the effects of 15-LOX-1 expression in mice fed high- or low-LA-content diets on CRC (tumor incidence and multiplicity), crypt proliferative zone length (Ki-67 IHC), activated B-catenin protein levels, and Wnt/B-catenin target gene (c-Myc, Cyclin D1, and Axin2) mRNA levels. For aim 2, we will replace 12-S-LOX in intestinal epithelial cells of 12/15-LOX knockout mice to generate mice with functional 15-LOX-1 loss and examine the effects in mice fed high- or low-LA-content diets on AOM-induced CRC, crypt proliferative zone length, and 13- HODE levels. We will also evaluate the effect of 15-LOX-1 gain of function (aim 1) and downregulation (aim 2) in human colonic cancerous and normal organoids (isolated from patients' colonic crypts) and cultured with various concentrations of LA on 13-HODE generation, cell proliferation, cell differentiation, and Wnt/B-catenin signaling. Aim 3: Determine the tempora and spatial effects of 15-LOX-1 expression in colonic epithelial cells on CRC tumorigenesis in relation to dietary LA intake. We will generate mice with conditional 15-LOX-1 expression, treat them with AOM, and feed them high- or low-LA-content diets. 15-LOX-1 expression will be induced during initiation or progression of CRC tumorigenesis, and we will examine the effects on the outcomes measured in aim 1. We expect these studies to provide important new information to direct development of novel interventions for CRC prevention and to identify subjects with low 15-LOX-1 expression as having increased risk of CRC tumorigenesis with high LA intake.
描述(由申请人提供):亚油酸(LA)在人体中的消耗量很高。LA增加了氧化偶氮甲烷(AOM)诱导的啮齿动物结直肠肿瘤发生,但LA对人类结直肠癌(CRC)的影响尚不清楚。15-脂氧合酶-1(15-LOX-1)是LA氧化代谢产生13-S-HODE(一种天然的PPAR-γ活化配体)的限速酶。PPAR-gamma抑制异常Wnt/B-连环蛋白信号传导,这是启动和驱动CRC肿瘤发生的关键事件。15-LOX-1在人类结直肠息肉和CRC中下调,但15-LOX-1对CRC风险的饮食LA调节的影响尚不清楚。在小鼠体内,我们发现转基因15-LOX-1表达抑制了CRC肿瘤的发生,并且在所有实验诱导的肿瘤中15-LOX-1表达下调。此外,在15-LOX-1-Gut小鼠中,用高LA饮食浓度的AOM诱导的CRC的增加被抑制;并且15-LOX-1抑制B-连环蛋白活化。因此,我们假设结肠上皮细胞中的15-LOX-1缺失对于过量LA通过增强Wnt/B-连环蛋白信号传导促进CRC肿瘤发生至关重要。我们将通过3个具体目的来检验这一假设:目的1和2:确定结肠上皮细胞中15-LOX-1表达(目的1)和表达缺失(目的2)对饮食LA促进CRC肿瘤发生和异常Wnt/B-连环蛋白信号传导的影响。为了实现目标1,我们将饲养15-LOX-1-Gut和Apc 580 mu小鼠,以产生Apc 580 mu-15-LOX-1-Gut小鼠,并检查喂食高或低LA含量饮食的小鼠中15-LOX-1表达对CRC的影响(肿瘤发生率和多样性),隐窝增殖区长度(Ki-67 IHC)、活化B-连环蛋白水平和Wnt/B-连环蛋白靶基因(c-Myc、细胞周期蛋白D1和Axin 2)mRNA水平。对于目标2,我们将替换12/15-LOX敲除小鼠的肠上皮细胞中的12-S-LOX以产生具有功能性15-LOX-1损失的小鼠,并检查喂食高或低LA含量饮食的小鼠对AOM诱导的CRC、隐窝增殖区长度和13- HODE水平的影响。我们还将评估15-LOX-1在人结肠癌性和正常类器官(从患者的结肠隐窝分离)中的功能获得(目的1)和下调(目的2)并与各种浓度的LA一起培养对13-HODE产生、细胞增殖、细胞分化和Wnt/B-连环蛋白信号传导的影响。目标三:确定结肠上皮细胞中15-LOX-1表达对CRC肿瘤发生的时间和空间效应与饮食LA摄入量的关系。我们将产生具有条件性15-LOX-1表达的小鼠,用AOM治疗它们,并给它们喂食高或低LA含量的饮食。15-LOX-1表达将在CRC肿瘤发生的开始或进展期间被诱导,并且我们将检查对目标1中测量的结果的影响。我们预计这些研究将提供重要的新信息,以指导开发预防CRC的新型干预措施,并确定15-LOX-1表达低的受试者在摄入高LA的情况下患CRC肿瘤的风险增加。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Imad Shureiqi其他文献
Imad Shureiqi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Imad Shureiqi', 18)}}的其他基金
ALOX15 regulation of colon cancer invasiveness via PI3P-linoleic acid metabolism
ALOX15 通过 PI3P-亚油酸代谢调节结肠癌侵袭力
- 批准号:
10339182 - 财政年份:2022
- 资助金额:
$ 35.29万 - 项目类别:
ALOX15 regulation of colon cancer invasiveness via PI3P-linoleic acid metabolism
ALOX15 通过 PI3P-亚油酸代谢调节结肠癌侵袭性
- 批准号:
10545078 - 财政年份:2022
- 资助金额:
$ 35.29万 - 项目类别:
15-LOX-1 Modulation of Colon Cancer Promotion by Linoleic Acid
亚油酸对 15-LOX-1 促进结肠癌的调节
- 批准号:
10330050 - 财政年份:2021
- 资助金额:
$ 35.29万 - 项目类别:
15-LOX-1 regulation of resolving generation to modulate colon cancer
15-LOX-1 调节分解生成以调节结肠癌
- 批准号:
10301423 - 财政年份:2016
- 资助金额:
$ 35.29万 - 项目类别:
15-LOX-1 Regulation of Resolving Generation to Modulate Colon Cancer
15-LOX-1 调节分解生成以调节结肠癌
- 批准号:
9980183 - 财政年份:2016
- 资助金额:
$ 35.29万 - 项目类别:
15-LOX-1 Regulation of Resolving Generation to Modulate Colon Cancer
15-LOX-1 调节分解生成以调节结肠癌
- 批准号:
9187612 - 财政年份:2016
- 资助金额:
$ 35.29万 - 项目类别:
Molecular targeting of PPAR-delta in colon cancer
结肠癌中 PPAR-δ 的分子靶向
- 批准号:
7987654 - 财政年份:2010
- 资助金额:
$ 35.29万 - 项目类别:
Molecular targeting of PPAR-delta in colon cancer
结肠癌中 PPAR-δ 的分子靶向
- 批准号:
8259197 - 财政年份:2010
- 资助金额:
$ 35.29万 - 项目类别:
Molecular targeting of PPAR-delta in colon cancer
结肠癌中 PPAR-δ 的分子靶向
- 批准号:
8091356 - 财政年份:2010
- 资助金额:
$ 35.29万 - 项目类别:
Molecular targeting of PPAR-delta in colon cancer
结肠癌中 PPAR-δ 的分子靶向
- 批准号:
8657861 - 财政年份:2010
- 资助金额:
$ 35.29万 - 项目类别:
相似海外基金
Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
- 批准号:
10760051 - 财政年份:2023
- 资助金额:
$ 35.29万 - 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
- 批准号:
2303692 - 财政年份:2023
- 资助金额:
$ 35.29万 - 项目类别:
Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
- 批准号:
468168 - 财政年份:2022
- 资助金额:
$ 35.29万 - 项目类别:
Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10427960 - 财政年份:2022
- 资助金额:
$ 35.29万 - 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
- 批准号:
10577074 - 财政年份:2022
- 资助金额:
$ 35.29万 - 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
- 批准号:
486588 - 财政年份:2022
- 资助金额:
$ 35.29万 - 项目类别:
Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
- 批准号:
2760091 - 财政年份:2022
- 资助金额:
$ 35.29万 - 项目类别:
Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10621188 - 财政年份:2022
- 资助金额:
$ 35.29万 - 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
- 批准号:
10891016 - 财政年份:2021
- 资助金额:
$ 35.29万 - 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
- 批准号:
10230365 - 财政年份:2020
- 资助金额:
$ 35.29万 - 项目类别: